AtriCure (NASDAQ:ATRC) Director Sven Wehrwein Sells 25,000 Shares

AtriCure, Inc. (NASDAQ:ATRC) Director Sven Wehrwein sold 25,000 shares of the business’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $37.84, for a total value of $946,000.00. Following the transaction, the director owned 40,518 shares in the company, valued at approximately $1,533,201.12. This represents a 38.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

AtriCure Stock Down 1.8%

Shares of ATRC stock traded down $0.74 during trading hours on Thursday, reaching $40.15. The company had a trading volume of 906,805 shares, compared to its average volume of 800,251. The company has a market capitalization of $2.04 billion, a P/E ratio of 191.20 and a beta of 1.24. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.18 and a current ratio of 4.22. AtriCure, Inc. has a twelve month low of $25.36 and a twelve month high of $43.18. The stock’s fifty day simple moving average is $30.68 and its 200 day simple moving average is $31.30.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The firm had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period in the previous year, the company posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, sell-side analysts expect that AtriCure, Inc. will post 0.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ATRC. Wall Street Zen downgraded shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. Canaccord Genuity Group lifted their price target on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Freedom Capital upgraded shares of AtriCure to a “strong-buy” rating in a report on Wednesday, April 1st. Raymond James Financial set a $52.00 price objective on shares of AtriCure in a research report on Tuesday, July 21st. Finally, Zacks Research upgraded AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 24th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $48.50.

Hedge Funds Weigh In On AtriCure

Several institutional investors and hedge funds have recently made changes to their positions in the business. Smartleaf Asset Management LLC increased its stake in shares of AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after buying an additional 429 shares during the last quarter. Scotia Capital Inc. boosted its stake in AtriCure by 1.2% during the 3rd quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock valued at $1,328,000 after acquiring an additional 457 shares during the last quarter. ProShare Advisors LLC boosted its stake in AtriCure by 6.6% during the 4th quarter. ProShare Advisors LLC now owns 8,819 shares of the medical device company’s stock valued at $349,000 after acquiring an additional 543 shares during the last quarter. Captrust Financial Advisors boosted its stake in AtriCure by 7.9% during the 4th quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company’s stock valued at $314,000 after acquiring an additional 579 shares during the last quarter. Finally, Mackenzie Financial Corp grew its holdings in AtriCure by 5.3% during the 4th quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company’s stock worth $545,000 after acquiring an additional 683 shares in the last quarter. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.